Staging and Surgical Treatment

  • Mario M. LeitaoJrEmail author
  • Richard R. Barakat
Part of the Cancer Treatment and Research book series (CTAR, volume 149)


The treatment of ovarian cancer truly involves a multimodal approach with surgery as the cornerstone. Surgery serves many roles in addition to providing a definitive diagnosis. In disease grossly confined to the ovary and/or pelvis, surgery can provide accurate and comprehensive staging based on the known patterns of spread. Many patients with clinically apparent early-stage ovarian cancer will be upstaged after comprehensive surgical staging. Accurate staging is crucial for a credible prognosis and as a guide for additional therapeutic approaches. The role of surgery for grossly advanced ovarian cancer is cytoreduction (debulking) of large tumor volume, which results in improved outcomes. Surgical cytoreduction also may improve the survival in select patients with recurrent disease. Surgery is considered in the palliation of many symptoms of advanced ovarian cancer. Patients with ovarian cancer will benefit from being treated by physicians with special expertise in the...


Ovarian Cancer Epithelial Ovarian Cancer Fertility Preservation Gynecologic Oncology Group Ovarian Borderline Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Pecorelli S, Ngan HYS, Hacker NF. Staging classifications and clinical practice guidelines for gynaecological cancers: FIGO Committee on Gynecologic Oncology. Int J Gynecol Obstet.2000;70:207–312.CrossRefGoogle Scholar
  2. 2.
    Pomel C, Provencher D, Dauplat J, et al. Laparoscopic staging of early ovarian cancer. Gynecol Oncol.1995;58:301–306.CrossRefPubMedGoogle Scholar
  3. 3.
    Childers JM, Lang J, Surwit EA, Hatch KD. Laparoscopic surgical staging of ovarian cancer. Gynecol Oncol. 1995;59:25–33.CrossRefPubMedGoogle Scholar
  4. 4.
    Leblanc E, Querleu D, Narducci F, Occelli B, Papageorgiou T, Sonoda Y. Laparoscopic restaging of early stage invasive adnexal tumors: a 10-year experience. Gynecol Oncol. 2004;94:624–629.CrossRefPubMedGoogle Scholar
  5. 5.
    Tozzi R, Kohler C, Ferrara A, Schneider A. Laparoscopic treatment of early ovarian cancer: surgical and survival outcomes. Gynecol Oncol. 2004;93:199–203.CrossRefPubMedGoogle Scholar
  6. 6.
    Lecuru F, Desfeux P, Camatte S, Bissery A, Blanc B, Querleu D. Impact of initial surgical access on staging and survival of patients with stage I ovarian cancer. Int J Gynecol Cancer. 2006;16:87–94.CrossRefPubMedGoogle Scholar
  7. 7.
    Chi DS, Abu-Rustum NR, Sonoda Y, et al. The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers. Am J Obstet Gynecol. 2005;192:1614–1619.CrossRefPubMedGoogle Scholar
  8. 8.
    Ghezzi F, Cromi A, Uccella S, et al. Laparoscopy versus laparotomy for the surgical management of apparent early stage ovarian cancer. Gynecol Oncol. 2007;105:409–413.CrossRefPubMedGoogle Scholar
  9. 9.
    Park J, Kim D, Suh D, et al. Comparison of laparoscopy and laparotomy in surgical staging of early-stage ovarian and fallopian tubal cancer. Ann Surg Oncol. 2008;15:2012–2019.CrossRefPubMedGoogle Scholar
  10. 10.
    Abu-Rustum NR, Rhee EH, Chi DS, Sonoda Y, Gemignani M, Barakat RR. Subcutaneous tumor implantation after laparoscopic procedures in women with malignant disease. Obstet Gynecol. 2004;103:480–487.CrossRefPubMedGoogle Scholar
  11. 11.
    Young RC, Decker DG, Wharton JT, et al. Smith JP. Staging laparotomy in early ovarian cancer. JAMA. 1983;250:3072–3076.CrossRefPubMedGoogle Scholar
  12. 12.
    Le T, Adolph A, Krepart GV, Lotocki R, Heywood MS. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Gynecol Oncol. 2002;85:351–355.CrossRefPubMedGoogle Scholar
  13. 13.
    Petru E, Lahousen M, Tamussino K, et al. Lymphadenectomy in stage I ovarian cancer. Am J Obstet Gynecol. 1994;170:656–662.PubMedGoogle Scholar
  14. 14.
    Cass I, Li AJ, Runowicz CD, et al. Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. Gynecol Oncol. 2001;80:56–61.CrossRefPubMedGoogle Scholar
  15. 15.
    Tsumura N, Sakuragi N, Hareyama H, et al. Distribution pattern and risk factors of pelvic and para-aortic lymph node metastasis in epithelial ovarian carcinoma. Int J Cancer. 1998;79:526–530.CrossRefPubMedGoogle Scholar
  16. 16.
    Trimbos JB, Vergote I, Bolis G, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer – adjuvant chemotherapy in ovarian neoplasm trial. J Natl Cancer Inst. 2003;95:113–125.CrossRefPubMedGoogle Scholar
  17. 17.
    Arango HA, Hoffman MS, Roberts WS, DeCesare SL, Fiorica JV, Drake J. Accuracy of lymph node palpation to determine need for lymphadenectomy in gynecologic malignancies. Obstet Gynecol. 2000;95:553–556.CrossRefPubMedGoogle Scholar
  18. 18.
    Eltabbakh GH. Intraoperative clinical evaluation of lymph nodes in women with gynecologic cancer. Am J Obstet Gynecol. 2001;184:1177–1181.CrossRefPubMedGoogle Scholar
  19. 19.
    Trimble CL, Kosary C, Trimble EL. Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. Gynecol Oncol. 2002;86:34–37.CrossRefPubMedGoogle Scholar
  20. 20.
    Winter WE III, Kucera PR, Rodgers W, McBroom JW, Olsen C, Maxwell GL. Surgical staging in patients with ovarian tumors of low malignant potential. Obstet Gynecol. 2002;100:671–676.CrossRefPubMedGoogle Scholar
  21. 21.
    Lim-Tan SK, Cajigas HE, Scully RE. Ovarian cystectomy for serous borderline tumors: a follow-up study of 35 cases. Obstet Gynecol. 1988;72:775–781.PubMedGoogle Scholar
  22. 22.
    Morice P, Camatte S, El Hassan J, Pautier P, Duvillard P, Castaigne D. Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. Fertil Steril. 2001;75:92–96.CrossRefPubMedGoogle Scholar
  23. 23.
    Zanetta G, Rota S, Chiari S, Bonazzi C, Bratina G, Mangioni C. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol. 2001;19:2658–2664.PubMedGoogle Scholar
  24. 24.
    Brewer M, Gershenson DM, Herzog CE, Mitchell MF, Silva EG, Wharton JT. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol.1999;17:2670–2675.PubMedGoogle Scholar
  25. 25.
    Zanetta G, Bonazzi C, Cantu MG, et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol. 2001;19:1015–1020.PubMedGoogle Scholar
  26. 26.
    Suh-Burgmann E. Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study. Gynecol Oncol. 2006;103:841–847.CrossRefPubMedGoogle Scholar
  27. 27.
    Romagnolo C, Gadducci A, Sartori E, Zola P, Maggino T. Management of borderline ovarian tumors: results of an Italian multicenter study. Gynecol Oncol. 2006;101:255–260.CrossRefPubMedGoogle Scholar
  28. 28.
    Tinelli R, Tinelli A, Tinelli FG, Cicinelli E, Malvasi A. Conservative surgery for borderline ovarian tumors: a review. Gynecol Oncol. 2006;100:185–191.CrossRefPubMedGoogle Scholar
  29. 29.
    Colombo N, Chiari S, Maggioni A, Bucciolone L, Torri V, Mangioni C. Controversial issues in the management of early epithelial ovarian cancer: conservative surgery and role of adjuvant therapy. Gynecol Oncol. 1994;55:S47–S51.CrossRefPubMedGoogle Scholar
  30. 30.
    Zanetta G, Chiari S, Rota S, et al. Conservative surgery for stage I ovarian carcinoma in women of childbearing age. Br J Obstet Gynaecol. 1997;104:1030–1035.CrossRefPubMedGoogle Scholar
  31. 31.
    Raspagliesi F, Fontanelli R, Paladini D, di Re E. Conservative surgery in high-risk epithelial carcinoma. J Am Coll Surg. 1997;185:472–475.Google Scholar
  32. 32.
    Morice P, Wicart-Poque F, Rey A, et al. Results of conservative treatment in epithelial ovarian carcinoma. Cancer. 2001;92:2412–2418.CrossRefPubMedGoogle Scholar
  33. 33.
    Schilder JM, Thompson AM, DePRiest PD, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol. 2002;87:1–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Morice P, Leblanc E, Rey A, et al. Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de centre de Lutte Contre le Cancer) and SFOG (Societe Francaise d'Oncologie Gynecologique). Human Reprod. 2005;20:1379–1385.CrossRefGoogle Scholar
  35. 35.
    Kajiyama H, Shibata K, Suzuki S, et al. Is there any possibility of fertility-sparing surgery in patients with clear-cell carcinoma of the ovary? Gynecol Oncol. 2008;111(3):523–6.Google Scholar
  36. 36.
    Park J, Kim D, Suh D, et al.Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes. Gynecol Oncol. 2008;110(3):345–53.Google Scholar
  37. 37.
    Norton L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist. 2001;6 (Suppl 3):30–35.CrossRefPubMedGoogle Scholar
  38. 38.
    Goldie JH, Coldman JA. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979;63:1727–1733.PubMedGoogle Scholar
  39. 39.
    Boente MP, Chi DS, Hoskins WJ. The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery. Semin Oncol. 1998;25:326–334.PubMedGoogle Scholar
  40. 40.
    Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975;42:101–104.PubMedGoogle Scholar
  41. 41.
    Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994;170:974–980.PubMedGoogle Scholar
  42. 42.
    Chi DS, Eisenhauer EL, Lang J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol.2006;103:559–564.CrossRefPubMedGoogle Scholar
  43. 43.
    Crawford SC, Vasey PA, Paul J, Hay A, Davis JA, Kaye SB. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial. J Clin Oncol. 2005;23:8802–8811.CrossRefPubMedGoogle Scholar
  44. 44.
    Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol. 2000;78:269–274.CrossRefPubMedGoogle Scholar
  45. 45.
    Bristow RE, Tomacruz RS, Armstrong DK, Trimble El, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–1259.CrossRefPubMedGoogle Scholar
  46. 46.
    Chi DS, Franklin CC, Levine DA, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol. 2004;94:650–654.CrossRefPubMedGoogle Scholar
  47. 47.
    Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer. Gynecol Oncol. 2006;103:1083–1090.CrossRefPubMedGoogle Scholar
  48. 48.
    Aletti GD, Dowdy SC, Gostout BS, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006;107:77–85.CrossRefPubMedGoogle Scholar
  49. 49.
    Winter WE III, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2007;25:3621–3627.CrossRefPubMedGoogle Scholar
  50. 50.
    Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43.CrossRefPubMedGoogle Scholar
  51. 51.
    Goodman HM, Harlow BL, Sheets EE, et al. The role of cytoreductive surgery in the management of stage IV epithelial ovarian cancer. Gynecol Oncol. 1992;46:367–371.CrossRefPubMedGoogle Scholar
  52. 52.
    Curtin JP, Rizwan M, Venkatraman ES, Barakat RR, Hoskins WJ. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol. 1997;64:9–12.CrossRefPubMedGoogle Scholar
  53. 53.
    Liu PC, Benjamin I, Morgan MA, King SA, Mikuta JJ, Rubin SC. Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol. 1997;64:4–8.CrossRefPubMedGoogle Scholar
  54. 54.
    Munkarah AR, Hallum AV, Morris M, et al. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol. 1997;64:13–17.CrossRefPubMedGoogle Scholar
  55. 55.
    Bristow RE, Montz F, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72:278–287.CrossRefPubMedGoogle Scholar
  56. 56.
    Akahira J, Yoshikawa H, Shimizu Y, et al. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol. 2001;81:398–403.CrossRefPubMedGoogle Scholar
  57. 57.
    Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system. Gynecol Oncol. 2007;105:84–89.CrossRefPubMedGoogle Scholar
  58. 58.
    Juretzka MM, Abu-Rustum NR, Sonoda Y, et al. The impact of video-assisted thoracic surgery (VATS) in patients with suspected advanced ovarian malignancies and pleural effusions. Gynecol Oncol. 2007;104:670–674.CrossRefPubMedGoogle Scholar
  59. 59.
    Vergote I, Van Gorp T, Amant F, Neven P, Berteloot P. Neoadjuvant chemotherapy for ovarian cancer. Oncology (Williston Park). 2005;19:1615–1622.Google Scholar
  60. 60.
    Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol. 2006;103:1070–1076.CrossRefPubMedGoogle Scholar
  61. 61.
    McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med.1996;334:1–6.CrossRefPubMedGoogle Scholar
  62. 62.
    van der Burg MEL, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med. 1995;332:629–634.CrossRefPubMedGoogle Scholar
  63. 63.
    Rose PG, Nerenstone S, Clarke-Pearson D, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med. 2004;351:2489–2497.CrossRefPubMedGoogle Scholar
  64. 64.
    Bristow RE, Puri I, Chi DS. Secondary cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2008;108:S119.Google Scholar
  65. 65.
    Berek JS, Hacker NF, Lagasse LD, Nieberg RK, Elashoff RM. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gyneol. 1983;61:189–193.Google Scholar
  66. 66.
    Segna R, Dottino PR, Mandeli JP, Konsker K, Cohen CJ. Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol. 1993;11:434–439PubMedGoogle Scholar
  67. 67.
    Lichtenegger W, Sehouli J, Buchmann E, Karajanev C, Weidemann H. Operative results after primary and secondary debulking-operations in advanced ovarian cancer (AOC). J Obstet Gynaecol Res. 1998;24:447–451.CrossRefPubMedGoogle Scholar
  68. 68.
    Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer. 2000;88:144–153.CrossRefPubMedGoogle Scholar
  69. 69.
    Zang RY, Zhang ZY, Li ZT, et al. Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. J Surg Oncol. 2000;75:24–30.CrossRefPubMedGoogle Scholar
  70. 70.
    Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2001;83:504–512.CrossRefPubMedGoogle Scholar
  71. 71.
    Zang Ry, Li ZT, Zhang ZY, Cai SM. Surgery and salvage chemotherapy for Chinese women with recurrent advanced epithelial ovarian carcinoma: a retrospective case-control study. Int J Gynecol Cancer. 2003;13:419–427.CrossRefPubMedGoogle Scholar
  72. 72.
    Zang Ry, Li ZT, Tang J, et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer. 2004;100:1152–1161.CrossRefPubMedGoogle Scholar
  73. 73.
    Ayhan A, Gultekin M, Taskiran C, et al. The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience. Am J Obstet Gynecol.2006;194:49–56.CrossRefPubMedGoogle Scholar
  74. 74.
    Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006;106:1933–1939.CrossRefPubMedGoogle Scholar
  75. 75.
    Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13:1702–1710.CrossRefPubMedGoogle Scholar
  76. 76.
    Salani R, Santillan A, Zahurak ML, et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer.2007;109:685–691.CrossRefPubMedGoogle Scholar
  77. 77.
    Tebes SJ, Sayer RA, Palmer JM, Tebes CC, Martino MA, Hoffman MS. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2007;106:482–487.CrossRefPubMedGoogle Scholar
  78. 78.
    Leitao MM Jr, Kardos S, Barakat RR, Chi DS. Tertiary cytoreduction in patients with recurrent ovarian carcinoma. Gynecol Oncol. 2004;95:181–188.CrossRefPubMedGoogle Scholar
  79. 79.
    Karam AK, Santillan A, Bristow RE, et al. Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome. Gynecol Oncol. 2007;104:377–380.CrossRefPubMedGoogle Scholar
  80. 80.
    Bristow RE, Duska LR, Lambrou NC, et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer. 2000;89:1532–1540.CrossRefPubMedGoogle Scholar
  81. 81.
    Funt SA, Hricak H, Abu-Rustum N, Mazumdar M, Felderman H, Chi DS. Role of CT in the management of recurrent ovarian cancer. AJR Am J Roentgenol. 2004;182:393–398.PubMedGoogle Scholar
  82. 82.
    Sugarbaker PH. Management of peritoneal surface malignancy: appendix cancer and pseudomyxoma peritonei, colon cancer, gastric cancer, abdominopelvic sarcoma, and primary peritoneal malignancy. In: Bland Ki, Daly JM, Karakousis CP, eds. Surgical Oncology: Contemporary Principles and Practice. New York: McGraw-Hill; 2001:1149–1176.Google Scholar
  83. 83.
    Helm CW, Randall-Whitis L, Martin III RS, et al. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol. 2007;105:90–96.CrossRefPubMedGoogle Scholar
  84. 84.
    Cotte E, Glehen O, Mohammed F, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for chemoresistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg. 2007;31:1813–1820.CrossRefPubMedGoogle Scholar
  85. 85.
    Meyn RE, Corry PM, Fletcher SE, Demetriades M. Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminechloroplatinum(II). Cancer Res. 1980;40:1136–1139.PubMedGoogle Scholar
  86. 86.
    Alberts DS, Peng YM, Chen HS, Moon TE, Cetas TC, Hoeschele JD. Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model. J Natl Cancer Incst. 1980;65:455–461.Google Scholar
  87. 87.
    Feuer DJ, Broadley KE, Shepherd JH, Barton DPJ. Systematic review of surgery in malignant bowel obstruction in advanced gynecological and gastrointestinal cancer. Gynecol Oncol. 1999;75:313–322.CrossRefPubMedGoogle Scholar
  88. 88.
    van Ooijen B, van der Burg MEL, Planting AST, Siersema PD, Wiggers T. Surgical treatment or gastric drainage only for intestinal obstruction in patients with carcinoma of the ovary or peritoneal carcinomatosis of other origin. Surg Gynecol Obstet. 1993;176:469–474.PubMedGoogle Scholar
  89. 89.
    Ripamonti C, Bruera E. Palliative management of malignant bowel obstruction. Int J Gynecol Cancer. 2002;12:135–143.CrossRefPubMedGoogle Scholar
  90. 90.
    Winter WE III, McBroom JW, Carlson JW, Rose GS, Elkas JC. The utility of gastrojejunostomy in secondary cytoreduction and palliation of proximal intestinal obstruction in recurrent ovarian cancer. Gynecol Oncol. 2003;91:261–264.CrossRefPubMedGoogle Scholar
  91. 91.
    Pothuri B, Vaidya A, Aghajanian C, Venkatraman E, Barakat RR, Chi DS. Palliative surgery for bowel obstruction in recurrent ovarian cancer: an updated series. Gynecol Oncol. 2003;89:306–313.CrossRefPubMedGoogle Scholar
  92. 92.
    Mangili G, Aletti G, Frigerio L, et al. Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis. Int J Gynecol Cancer. 2005;15:830–835.CrossRefPubMedGoogle Scholar
  93. 93.
    von Gruenigen VE, Frasure HE, Reidy AM, Gil KM. Clinical disease course during the last year in ovarian cancer. Gynecol Oncol. 2003;90:619–624.CrossRefGoogle Scholar
  94. 94.
    Pothuri B, Montemarano M, Gerardi M, et al. Percutaneous endoscopic gastrotomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol Oncol. 2005;96:330–334.CrossRefPubMedGoogle Scholar
  95. 95.
    Brard L, Weitzen S, Strubel-Lagan SL, et al. The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients. Gynecol Oncol. 2006;103:176–180.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Department of Surgery, Division of GynecologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations